TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02056496

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Description: Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Description: Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).
Study: NCT03908580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: Meditoxin® (Botulinum toxin type A) was injected up to 360 U.
Study: NCT00527072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
Study: NCT04115527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended Lymphadenectomy
Description: Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 16 17a 17b lymph nodes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lymphadenectomy
Description: Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes
Study: NCT01105936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 665 mg sustained release paracetamol caplets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo caplets
Study: NCT01311739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyanocobalamin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyanocobalamin
Study: NCT02007252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: ACZ885 150 mg liquid pre-filled syringes were administered s.c..

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo liquid pre-filled syringes were administered s.c..
Study: NCT02019498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation exercise
Description: Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ususal care
Description: Participants allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
Study: NCT00854438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary drug reviews by pharmacist and physician
Description: Reduction of anticholinergic drug effects by pharmacist review
Study: NCT01197092

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mitochondrial preparations
Description: Oral therapy with mitochondrial preparations based on recipes of Dr Kremer and the Tisso company:~ProEMSan (large intestinal symbionts with 31 strains of bacteria) Pro Basan (small intestinal symbionts) ProSirtusan (Polyphenol-mix and vitamins) ProVita D3 (Vitamin D3 supplement) ProOmega (Omega 3-fatty acid preparation) ProCarnitin (Carnitine-preparation) ProSango Vital (trace element preparation)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Infusion therapy
Description: Infusion therapy in the form of a complex mix: 500ml-solution with trace elements, amino acids and antioxidants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Webermedical device
Description: Intravenous-Blood-Laser-Therapy: the Webermedical device will be used

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Description: Nutritional therapy based on IgG-blood results. Significant antibody-formation against foodstuffs will be ascertained (in foodstuffs evaluated through the BioMedicalScreen), will be taken out of the diet - the background being the additional lowering of risk potential of those antibodies causing the so called silent inflammation (sub-clinical inflammation) -ultimately an anti-inflammatory diet will be given in the protocol. The following have special focus: gluten, cow's milk, fish, meat, nuts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional therapy
Description: Nutritional therapy based on IgG-blood results. Significant antibody-formation against foodstuffs will be ascertained (in foodstuffs evaluated through the BioMedicalScreen), will be taken out of the diet - the background being the additional lowering of risk potential of those antibodies causing the so called silent inflammation (sub-clinical inflammation) -ultimately an anti-inflammatory diet will be given in the protocol. The following have special focus: gluten, cow's milk, fish, meat, nuts.
Study: NCT05156333

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Respecta
Description: Respecta® complex (mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).~Daily oral administration of two capsules of the Giellepi Spa class IIa medical device Respecta or placebo, to be taken with a glass of water preferably between meals, starting from the 30th week of pregnancy until the 37th week after having vagino-rectal swab screening performed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Respecta
Description: Respecta® complex (mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).~Daily oral administration of two capsules of the Giellepi Spa class IIa medical device Respecta or placebo, to be taken with a glass of water preferably between meals, starting from the 30th week of pregnancy until the 37th week after having vagino-rectal swab screening performed.
Study: NCT04107428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: A bolus of 5cc of saline containing 500 mcg of somatostatin will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 250 mcg per hour of somatostatin (infusion rate 2.5 cc/hour) for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A bolus of 5cc of saline will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 2.5 cc of saline/hour for 10 days.
Study: NCT02072746

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03208075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal diet
Description: Diet containing 1500mg of phosphorus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-phosphorus diet
Description: Diet containing 500mg of phosphorus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-phosphorus diet
Description: Diet containing 2300mg of phosphorus
Study: NCT00987610

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: PCI for chronic total occlusion is performed using either arm of guidewire

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: PCI for chronic total occlusion is performed using either arm of guidewire
Study: NCT02001688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kamada-AAT for Inhalation, 80mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kamada-AAT for Inhalation, 160mg
Study: NCT02311790

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans-C16:1 supplement
Description: Each volunteer will consume 3 escalating doses (120 mg/day, 240 mg/day and 480 mg/day) of trans-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cis-C16:1 supplement
Description: Each volunteer will consume 3 escalating doses (380 mg/day, 760 mg/day and 1520 mg/day) of cis-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]
Study: NCT03189407

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Moringa oleifera tea
Study: NCT02848313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elamipretide
Description: 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elamipretide
Description: 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.
Study: NCT02003118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKR 202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02530099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CN-group
Description: Time limited simulation based training on camera navigation tasks on a virtual reality-simulator.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure-group
Description: Time limited simulation based training on laparoscopic procedure on a virtual reality-simulator.
Study: NCT02732249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Given 30 min before morning and evening meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Given 30 min before morning and evening meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Given 30 min before morning and evening meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Given 30 min before morning and evening meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Given 30 min before morning and evening meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Given 30 min after morning and evening meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Given 30 min after morning and evening meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Given 30 min after morning and evening meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Given 30 min after meals or at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Given 30 min after meals or at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Given 30 min after meals or at bedtime
Study: NCT02152072

Intervention type: OTHER
Intervention: Using Simulation-Based Training to Incorporate Lung Ultrasound into Physical Examination
Study: NCT02477306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idiazole 20mg DR tabs
Description: Delayed release tablets containing 20 mg of rabeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARIET 20 mg DR tabs
Description: Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
Study: NCT01755325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound realgar natural indigo Tablet
Description: Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04250740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee with butter-1
Description: 250 mL brewed black coffee with hazelnut flavouring and 50 g water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee with butter-II
Description: 250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-I

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee with butter-III
Description: 250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-II
Study: NCT03395041

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac imaging tests
Description: cardiac computed tomography, echocardiography, intravascular ultrasound, optical coherence tomography

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac imaging tests
Description: cardiac computed tomography, echocardiography, intravascular ultrasound, optical coherence tomography
Study: NCT02919917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
Study: NCT02353676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 1.5 ml of 0.55 bupivacaine solution to be used as postoperative anesthetic agent for prolonged analgesia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SALINE
Description: 1.5 ml of placebo (saline solution) to be injected into the opposite site postoperatively.
Study: NCT03049605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Only medical treatment
Description: Fifteen patients with diabetic peripheral neuropathy were treated with antidiabtic drugs and lyrica 150 milligram daily
Study: NCT00144664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Study: NCT00895414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT02289339

Intervention type: DEVICE
Intervention: aortic valve prostheses
Description: balloon-expandable and self-expandable aortic valve prostheses
Study: NCT00895414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril maleate
Description: Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril maleate
Description: Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
Study: NCT04044911

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task model (CogWatch)
Study: NCT01637272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230
Description: Pasireotide (SOM230) sc injection was provided as solution for injection in individual 1-point-cut 1 mL ampule, containing nominally 200 μg of pasireotide (as free base). Doses: 50, 100, 150 and 200 μg. Pasireotide im LAR depot injection was provided as micro particles powder in vials containing nominally 10, 20, 40 \& 60 mg of pasireotide (as free base) \& solvent for suspension for injection in ampules for the reconstitution of the LAR micro particles. Doses: 10, 20, 30, 40 or 60 mg
Study: NCT02883270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted Gait Training
Description: Robot-assisted Gait Training is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation and provided to the feet and the patient actively controls the knee and hip joints.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional rehabilitation
Description: The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
Study: NCT03024060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA
Description: 20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA
Description: 20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
Study: NCT02390687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
Study: NCT03024060

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IBL 20 mW
Description: 10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IBL 20 mW
Description: 10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IBL 10 mW
Description: 10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IBL 10 mW
Description: 10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
Study: NCT06792240

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron supplementation
Description: The amount of supplementary iron was decided for patients according to the daily requirement (8- 18 mg / day), according to LARN 2012 and (RDAs) for Iron. (25) . This study took in consideration also, the recommendation of the National Institutes of Health iron dietary supplement fact of sheet as reference to calculate iron dose for our candidates because this dose isn't against LARN and more practical to applicate.~The minimum RDA values is applied, which coincides within the LARN daily requirement limits. (7 mg-18 mg of iron per day). Applying the minimum recommended RDA dose, that can satisfy the daily iron requirement by age, approximating it to be adequate for the clinical dose administered orally once a day (e.g. 1.98 g ==\> 2 g, 1.53 g ==\> 1.5 g

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: control group
Description: Non intervension: Only restricted low and controlled Phe diet therapy
Study: NCT00510367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 500 mg/m\^2 By Vein Daily x 2 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 By Vein On Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 By Vein Over 72 Hours
Study: NCT00757367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TI Inhalation Powder
Description: 1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
Study: NCT00110591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: Monoclonal antibody to CCR5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: Monoclonal antibody to CCR5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: Monoclonal antibody to CCR5
Study: NCT02957669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Self-Regulation
Description: PS-R is an in-person, individual-level, clinic-based intervention implemented by mental health professionals trained in the intervention. It is intended to be implemented in ten structured, individual therapy sessions lasting approximately 50 minutes over the course of 18 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy Practice Group
Description: Therapy Practice Group is the control condition aimed at providing the youth a safe space to work on meeting their mental health goals. It is intended to be at least ten sessions over the course of 18 weeks.
Study: NCT00143637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Office dust
Description: airborne office dust spiked with glucan
Study: NCT00110591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: Monoclonal antibody to CCR5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRO 140
Description: Monoclonal antibody to CCR5
Study: NCT04572698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY09004
Description: LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eylea
Description: EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
Study: NCT02719457

Intervention type: OTHER
Group type: OTHER
Intervention: 6 minute walk test (6 MWT)
Description: 6 minute walk test is the standard testing for COPD patients to evaluate their exercise capacity

Intervention type: OTHER
Group type: OTHER
Intervention: Spot marching test (SMT)
Description: Spot marching test is a new test that developed to evaluate their exercise capacity of COPD patients. This test is alternative method and practical to evaluate exercise capacity. The main benefit of this testing is use a small area to test and movement pattern involve both arm and leg. We expect that SMT may make COPD patient to more dyspnea in a short period of exercise.
Study: NCT05240963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporal PEEK implant
Description: Temporal PEEK implant to reconstruct temporal fossa after temporalis muscle transfer